On November 3, 2026, a trial update was recorded for the NeoAdjuvant Theranostic Lutetium Study, known as the Nautilus Trial. The study, registered as NCT06066437, involves degarelix, an approved compound. The trial is listed as Phase 1/2 and its current status is recruiting.
This update reflects the trial's registration status as of the date noted, with no results reported at this time. The Nautilus Trial is identified under the ClinicalTrials.gov registry, and its full protocol and eligibility details can be found through that listing. No outcome data, efficacy information, or safety findings are included in this update, as none have been reported for this stage of the trial.
Degarelix carries approved regulatory status, and its inclusion in this neoadjuvant theranostic study is noted here only as a matter of trial registration and recruitment status. No additional claims about the trial's purpose, design outcomes, or expected results beyond what is stated can be made at this time.
Readers interested in degarelix's broader profile and context can consult the compound overview page.